Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis.

Abstract

Temozolomide is a novel, oral, second-generation alkylating agent. Preclinical and phase I/II studies have demonstrated its efficacy against newly diagnosed high-grade glioma and anaplastic astrocytoma. Its antineoplastic effect is accompanied by quality of life benefits in patients with these debilitating tumors. Neoplastic meningitis, a refractory… (More)

Topics

Cite this paper

@article{Friedman2000TemozolomideIE, title={Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis.}, author={Heather S. Friedman}, journal={Seminars in oncology}, year={2000}, volume={27 3 Suppl 6}, pages={35-40} }